Janux therapeutics to present at upcoming march investor conferences

San diego--(business wire)--janux therapeutics, inc. (nasdaq: janx) (janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its tumor activated t cell engager (tractr) and tumor activated immunomodulator (tracir) platforms, today announced that janux management will participate in three upcoming investor conferences: cowen's 42nd annual health care conference forum: panel titled “novel io” location: virtual date: monday
JANX Ratings Summary
JANX Quant Ranking